Regulation A+, or Reg A equity crowdfunding is the 21st century way to raise capital. You no longer need to be an accredited investor with a seven-figure net worth to reap the rewards of investing. Under the Title IV provision of the 2012 Jumpstart Our Business Startups (JOBS) Act, which passed in 2015, both startups …
Regulation A: What Is It and What Does It Mean for Kurve? Read More »
$627 Billion. That was the estimated national cost of Alzheimer’s disease in 2021. That’s more than 10x Warren Buffett’s net worth. That’s more than most countries’ GDP. Central nervous system (CNS) disorders like Alzheimer’s disease are a global economic crisis. Without efficient treatments or a cure, Alzheimer’s remains the only disease in the top 10 …
*Founders, board, and management own 51% of common shares
16825 48th West Suite 434
Lynnwood, WA 98037
info@kurvetx.com
(425) 640-9249
Transfer Agent: KoreConX Inc. | Broker-Dealer: Rialto Markets LLC | Escrow Agent: Wilmington Trust NA The Refund Policy: There are no refunds or cancelations of commitments once the subscription agreement is signed and submitted. Please contact compliace@rialtomarkets.com with questions regarding a cancelation or refund.
The offering will be made only by means of an offering circular. An offering statement regarding this offering has been filed with the SEC. The SEC has qualified that offering statement which only means that the company may make sales of the securities described by that offering statement. It does not mean that the SEC has approved, passed upon the merits or passed upon the accuracy or completeness of the information in the offering statement. The securities offered by the company are highly speculative. Investing in shares of common stock of the company involves significant risks. The investment is suitable only for persons who can afford to lose their entire investment. Furthermore, investors must understand that such investment could be illiquid for an indefinite period of time. No public market currently exists for the securities, and if a public market develops following the offering, it may not continue. You may obtain a copy of the Form 1-A offering circular that is part of said offering statement here. You should read the offering circular before making any investment. The offering materials and this letter may contain forward-looking statements and information relating to, among other things, the company, its business plan and strategy, and its industry. These forward-looking statements are based on the beliefs of, assumptions made by, and information currently available to the company’s management. When used in the offering materials, the words “estimate,” “project,” “believe,” “anticipate,” “intend,” “expect” and similar expressions are intended to identify forward-looking statements, which constitute forward-looking statements. These statements reflect management’s current views with respect to future events and are subject to risks and uncertainties that could cause the company’s actual results to differ materially from those contained in the forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made. The company does not undertake any obligation to revise or update these forward-looking statements to reflect events or circumstances after such date or to reflect the occurrence of unanticipated events.
This investment involves a high degree of risk. This investment is suitable only for persons who can bear the economic risk for an indefinite period of time and who can afford to lose their entire investment. Furthermore, investors must understand that such investment is illiquid and is expected to continue to be illiquid for an indefinite period of time. No public market exists for the securities.
This information is presented only for the purpose of providing a general overview of clinical trials. These uses have not been approved by the U.S. Food and Drug Administration (FDA) or other regulatory authorities.
Copyright © 2022 Kurve Therapeutics